CD274 and neoplasm: These individuals often present low PD‐L1 expression and insufficient T‐cell infiltration within the tumor microenvironment, resulting in suboptimal clinical outcomes with ICB monotherapy.[3] Immunogenic cell death (ICD) of tumor cells can release tumor‐specific antigens and damage‐associated molecular patterns (DAMPs),[4] triggering further activation, proliferation, and infiltration of T‐cells in the tumor microenvironment, and enhancing T‐cell activity.[5] Therefore, the combination of ICD and ICB has emerged as a promising synergistic treatment approach.